Floatz logo

Lifileucel

Locally Advanced Refractory/Recurrent Head and Neck Cancer

Gregory DanielsCell therapyPhase 2Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
95/ 100

Competitive context

250 Active assets in the Locally Advanced Refractory/Recurrent Head and Neck Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Akeso
Phase 3BB
Carboplatin
Akeso
Phase 4BB
Irinotecan
Neonc Technologies, Inc.
Phase 2BB
Tisotumab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2BB
Capecitabine
Merck Sharp & Dohme LLC
Phase 2BB

View all 50 →

Same molecule, other indications

Lifileucel is also rated in:

melanomaDormant
BB
Indicative ·
66 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
66 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →